Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study

Anneli Enblom‐Larsson(Umeå University), Anders Själander(Umeå University), Henrik Holmberg(Centre of Registers Vastra Gotaland), Björn Andréasson(NU Hospital Group), Maria Liljeholm(University Hospital of Umeå)
European Journal Of Haematology
February 2, 2023
10.1111/ejh.13938
Cited by 3

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
|Blood|2011|340
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
|Blood|2014|153